MT news Reporter Yu-mi Lee

AdipoLABs will participate in the Korea International Medical and Hospital Equipment Show (KIMES 2019), which will be held at COEX, Seoul, Korea, from 14th to 17th, and will hold export contracts and consultation sessions.

Han Sung-ho, CEO of AdipoLABs said that "In India, as well as other countries, interest in 'REMISSION 1℃' is increasing.", “We will try to deliver a miracle of 1 ℃ to cancer patients around the world."

‘REMISSION 1℃' is a cancer treatment device developed and produced with pure domestic technology. It is a device that has the principle of generating frictional heat by applying high-frequency to human body. Deep heat rises and the internal organs heat up, killing cancer cells that lose their ability to dissipate heat. NK cells are also activated. The Catholic University of Korea Seoul St. Mary's Hospital, Oxymed Hospital (India), and Gulizstan National Cancer Center (Uzbekistan) are using this equipment.

AdipoLABs introduced 'High-frequency Hyperthermia Cancer Treatment, REMISSION 1℃' for medical personnel in India and abroad at this exhibition in New Delhi, India.

AdipoLABs Healthcare India is a joint venture established by AdipoLABs to enter the UNHHD jurisdiction. It plans to export medical devices to India and neighboring countries through local subsidiaries.

AdipoLABs (CEO Han Sung-ho), a specialist in high-frequency medical devices, recently participated in HEALTH TECH INDIA 2019 through 'AdipoLABs Healthcare India'. On this occasion, the company announced on the 7th that they will speed up the targeting of India market.